...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cytokine >Quantitative analysis of serum chemokines associated with treatment failure of direct-acting antivirals in chronic hepatitis C
【24h】

Quantitative analysis of serum chemokines associated with treatment failure of direct-acting antivirals in chronic hepatitis C

机译：慢性丙型肝炎直接作用抗病毒治疗失效相关的血清趋化因子的定量分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Although serum chemokine levels have been reported to influence the outcome of interferon-based treatment in patients with chronic hepatitis C, their effect on the hepatitis C virus (HCV) response to direct-acting antiviral agents (DAAs), which can achieve high rates of a sustained virological response (SVR), is largely unknown. To clarify this relationship, 9 chemokines (eotaxin, GRO-alpha, IL-8, IP-10, MCP-1, MIP-1 alpha, mip-1 beta, RANTES, and SDF-1 alpha) were quantified before, during, and after DAA treatment using serum samples obtained from 57 patients with chronic hepatitis C. All baseline median chemokine levels were significantly higher in patients with chronic hepatitis C than in healthy subjects (P 0.05). In particular, lower MIP-1 beta (= 71.5 pg/mL) and higher RANTES ( 671.5 pg/mL) levels were significantly associated with patients who failed to clear HCV RNA (P = 0.0039 and 0.013, respectively). Prediction of a clinical response based on a combination of these chemokines demonstrated high sensitivity (82%), specificity (85%), negative predictive value (95%), and area under the curve (0.833). The non-SVR rate (56.3%; 9 of 16) was significantly higher in patients with low MIP-1 beta and high RANTES compared with other combinations. Moreover, baseline mip-1 beta and RANTES were both additive and independent for predicting a non-SVR. Apart from an increase in eotaxin, all chemokines became decreased in patients with a SVR. In conclusion, a combination of serum MIP-1 beta and RANTES levels may be predictive of a treatment response to DAAs in Japanese patients with chronic hepatitis C.
机译：据报道，虽然据报道血清趋化因子水平影响慢性丙型肝炎患者的干扰素类治疗的结果，但它们对丙型肝炎病毒（HCV）对直接作用抗病毒剂（DAAS）的影响，尽管可以实现高速率的丙型肝炎病毒（HCV）反应持续的病毒学反应（SVR）在很大程度上是未知的。为了澄清这种关系，在之前，期间，在期间，测量了9个趋化因子（Etaxin，Gro-α，IL-8，IP-10，MCP-1，MIP-1α，MIP-1β，Rantes和SDF-1α）。除了从57例慢性丙型肝炎患者中获得的DAA治疗后，慢性丙型肝炎患者的所有基线中值趋化因子均显着高于健康受试者（P <0.05）。特别地，降低MIP-1β（＆ = 71.5pg / ml）和更高的咆哮（＆ 671.5 pg / ml）水平与未能透明HCV RNA的患者显着相关（分别分别p = 0.0039和0.013）。基于这些趋化因子的组合预测临床反应，证明了高灵敏度（82％），特异性（85％），曲线下的面积（0.833）。与其他组合相比，低MIP-1β和高咆哮的患者，非SVR率（56.3％）显着高。此外，基线MIP-1β和RANTES都是添加剂，并且与预测非SVR无关。除了ETOXIN的增加外，SVR患者均趋化因子降低。总之，血清MIP-1β和RANTES水平的组合可以预测日本慢性丙型肝炎患者对DAA的治疗反应。

著录项

  • 来源
    《Cytokine》 |2018年第2018期|共7页
  • 作者

    Umemura Takeji; Yamazaki Tomoo; Joshita Satoru; Sugiura Ayumi; Fujimori Naoyuki; Matsumoto Akihiro; Ota Masao; Tanaka Eiji;

  • 作者单位

    Shinshu Univ Sch Med Div Gastroenterol &

    Hepatol Dept Med Matsumoto Nagano Japan;

    Shinshu Univ Sch Med Div Gastroenterol &

    Hepatol Dept Med Matsumoto Nagano Japan;

    Shinshu Univ Sch Med Div Gastroenterol &

    Hepatol Dept Med Matsumoto Nagano Japan;

    Shinshu Univ Sch Med Div Gastroenterol &

    Hepatol Dept Med Matsumoto Nagano Japan;

    Shinshu Univ Sch Med Div Gastroenterol &

    Hepatol Dept Med Matsumoto Nagano Japan;

    Shinshu Univ Sch Med Div Gastroenterol &

    Hepatol Dept Med Matsumoto Nagano Japan;

    Shinshu Univ Sch Med Div Gastroenterol &

    Hepatol Dept Med Matsumoto Nagano Japan;

    Shinshu Univ Sch Med Div Gastroenterol &

    Hepatol Dept Med Matsumoto Nagano Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 细胞生物学;
  • 关键词

    Hepatitis C virus; Direct-acting antiviral agents; MIP-1 beta; RANTES; Biomarker;

    机译：丙型肝炎病毒;直接作用抗病毒剂;MIP-1 beta;rantes;生物标志物;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号